Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells—an in-vitro study

Table 5 Adjusted p-values (Bonferroni’s multiple comparisons test) for cisplatin applications comparison of different cell types, level of significance for CAP + Cis cc, p ≤ 0.0221 and for CAP + Cis cs, p ≤ 0.041

Adjusted p- value for CAP + Cis cc application						Adjusted p- value for CAP + Cis cs application
Cell lines	30 s	60 s	90 s	120 s	180 s	30 s	60 s	90 s	120 s	180 s
Cal 27 vs. FaDu	0.0119	> 0.9999	< 0.0001	< 0.0001	< 0.0001	0.5175	> 0.9999	0.0032	< 0.0001	0.0003
Cal 27 vs. OSC 19	0.0012	0.0001	0.0011	0.801	< 0.0001	> 0.9999	> 0.9999	> 0.9999	< 0.0001	< 0.0001
FaDu vs. OSC 19	< 0,.001	< 0.0001	< 0.0001	< 0.0001	> 0.9999	> 0.9999	> 0.9999	0.0413	0.0041	0.453

ISSN: 1746-160X